| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
14.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $244.6 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
100,397 |
5,364,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$15,909,372 |
$1,039,781,980 |
$1,085,894,829 |
| Total People Sold |
2 |
2 |
8 |
9 |
| Total Sell Transactions |
6 |
6 |
20 |
54 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang Jane |
CMO, Hematology |
• – – |
2020-05-29 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2020-05-19 |
4 |
S |
$169.84 |
$1,698,400 |
D/D |
(10,000) |
0 |
|
-79% |
|
| Glazer Donald W. |
Director |
– • – |
2020-05-19 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,680 |
3,497,678 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-05-01 |
4 |
S |
$140.96 |
$655,537 |
D/D |
(4,635) |
0 |
|
-78% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-05-01 |
4 |
S |
$140.96 |
$992,711 |
D/D |
(7,024) |
0 |
|
-78% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-04-29 |
4 |
AS |
$162.30 |
$243,450 |
D/D |
(1,500) |
0 |
|
49% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-04-29 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-04-16 |
4 |
AS |
$160.00 |
$240,000 |
D/D |
(1,500) |
0 |
|
61% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-04-16 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-03-04 |
4 |
AS |
$156.82 |
$785,681 |
D/D |
(5,000) |
0 |
|
50% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-02-18 |
4 |
AS |
$170.01 |
$255,380 |
D/D |
(1,500) |
0 |
|
14% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-02-18 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-01-21 |
4 |
AS |
$170.09 |
$256,042 |
D/D |
(1,500) |
0 |
|
-3% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-01-21 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2020-01-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
206,635,013 |
|
-2% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2019-12-17 |
4 |
AS |
$158.63 |
$10,000,100 |
D/D |
(62,259) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-12-16 |
4 |
AS |
$160.07 |
$247,710 |
D/D |
(1,500) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-12-16 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2019-11-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
81,060 |
3,630,366 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-11-18 |
4 |
AS |
$192.24 |
$291,740 |
D/D |
(1,500) |
0 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2019-11-18 |
4 |
OE |
$29.49 |
$44,235 |
D/D |
1,500 |
1,500 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-11-18 |
4 |
AS |
$191.80 |
$4,858,616 |
D/D |
(25,000) |
0 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2019-11-18 |
4 |
OE |
$6.50 |
$162,500 |
D/D |
25,000 |
25,000 |
|
- |
|
| Wu Xiaobin |
President & GM China |
• – – |
2019-11-15 |
4 |
AS |
$202.05 |
$202,050 |
D/D |
(1,000) |
0 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2019-11-15 |
4 |
AS |
$202.05 |
$79,810 |
I/I |
(395) |
0 |
|
- |
|
527 Records found
|
|
Page 13 of 22 |
|
|
1.40 (0.86%) 
